Figure 6. Crucial SARS-CoV-2 targets for novel antiviral drug
development.
The last point of view is the application of small interfering RNAs
(siRNAs). SARS-CoV-2 can disintegrate in host cells, releasing the
nucleocapsid and viral RNA into the cytoplasm, and then translate ORF1a
/ b into pp1a and pp1ab for genomic RNA replication (van Boheemen et
al., 2012). Hence, siRNAs targeting structural genes may play a role in
the SARS-CoV-2 infections, and further optimizing the delivery of siRNAsin vivo may make them clinically valuable.